text:
"Diversity: the art of thinking independently together"
– Malcolm Stevenson Forbes
By delivering breakthrough therapies that can harness the immune system, we aim to conquer cancer and save lives
Amunix is an immuno-oncology company leveraging our proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer. We aim to expand the therapeutic index of TCEs and cytokines, which have demonstrated anti-tumor clinical activity, but have not realized their potential due to dose-limiting on-target, off-tumor toxicity.
We address this challenge by using our universal, protease-releasable masking technology (Pro-XTEN), to create next generation, conditionally active TCEs (XPATs®) and cytokines (XPACs), that are preferentially activated in tumors as compared to healthy tissues.
Experience and culture matter. At Amunix, we challenge ourselves and our colleagues, and bring a critical eye and rigor to everything we do. Biology is complex and hard to predict, but with deep experience, diversity of thinking, and scientific rigor, we believe we maximize our chance of making a real difference for cancer patients.
Mika Kakefuda Derynck, M.D.
Maninder Hora, Ph.D.
Chief Technical Operations Officer
Bryan Irving, Ph.D.
Anne Keane, J.D.
Senior Vice President of Regulatory and Quality
Zeeshan Merchant
Darcy Mootz, Ph.D.
Chief Business Officer
Volker Schellenberger, Ph.D.
President and Chief Technology Officer
Angie You, Ph.D.
Additional Senior Management
Nicky Barber, CPA
Katherine Bock
Vice President of Investor Relations & Corporate Communications
Michelle Heath
Head of People
Vice President of Contracts
Ursula McCurry
Vice President of Clinical Operations
Nabeela Rasheed, Ph.D., J.D.
Vice President of Intellectual Property
Geetha Shankar, Ph.D.
Vice President of Clinical Science and Clinical Operations
Gary T. Taniguchi, Ph.D.
VICE PRESIDENT OF BIOANALYTICAL SCIENCES
Dr. Derynck is the Chief Medical Officer of Amunix. She is an accomplished drug developer with over 25 years of experience in cancer research, including a 15-year career at Genentech/Roche. She has deep expertise in oncology drug development, which spans multiple therapeutic modalities, tumor types, and all phases of development. During her tenure at Genentech/Roche, she oversaw the approvals and/or global development for over a dozen drugs, including Perjeta®, Avastin®, Tecentriq®, Cotellic®, ipatasertib, taselisib, pictilisib, and apitolisib. Most recently, she served as the Global Head for Cancer Immunotherapy, GI/GU Cancers, Angiogenesis Franchises and China Oncology Development. She also served as the Co-Chair of the Cancer Immunotherapy Committee (CITC), the GI/GU Franchises Committee, and the Breast Cancer Disease Area Team. Dr. Derynck was also a Senior Group Medical Director of Exploratory Clinical Development at Genentech, serving as the development lead for multiple early-stage programs. Before Genentech, Dr. Derynck was an Assistant Clinical Professor in the UCSF Department of Cellular and Molecular Pharmacology and Division of Hematology / Oncology. Dr. Derynck holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. She completed an internal medicine residency at Johns Hopkins, followed by a fellowship in Hematology / Oncology at UCSF and a postdoctoral fellowship at UCSF.
Dr. Maninder Hora currently serves as the Chief Technical Operations Officer of Amunix. Dr. Hora has served the biopharmaceutical industry for more than 30 years with demonstrated leadership in process, analytical and pharmaceutical sciences, manufacturing and quality functions. He has been part of teams that have successfully filed 50+ INDs and registered 11 biopharmaceutical products worldwide. Prior to joining Amunix, he served as the Chief Technical Operations Officer of Nektar Therapeutics, where he spearheaded strategic direction and execution of all process and product development as well as manufacturing activities. Prior to Nektar, he served as Vice President of Product Operations & Quality at Facet Biotech/ PDL BioPharma (now a part of Abbvie) and Vice President of Process and Product Development at Chiron Corporation (now Novartis). Prior to that, he held positions of increasing responsibilities at Chiron, Pfizer and GSK.
Dr. Hora received his Ph.D. from the Indian Institute of Technology in Bioengineering (Materials) in 1980 and held a Fulbright fellowship at the University of Washington, Seattle. He holds 23 US Patents and has authored scores of publications and delivered numerous presentations in international forums. He serves on the Scientific Advisory Board for Cristal Therapeutics, an emerging nanotechnology-based biopharmaceutical company.
Dr. Bryan Irving currently serves as the Chief Scientific Officer of Amunix. He has 30 years of experience in immunology, with nearly 20 years in industry focused on discovering and progressing immune drug candidates into the clinic for both autoimmune and oncology indications. Prior to joining Amunix, he served as Chief Scientific Officer of Five Prime Therapeutics, where he led research and preclinical drug development, and as Vice President of Cancer Immunology at CytomX Therapeutics, where he led immune applications of their protease-activatable, prodrug technology (included T cell bispecifics and T cell checkpoint targets). Prior to CytomX, he worked 12 years as a scientist at Genentech in the Departments of Immunology and Oncology/Cancer Immunology, where he was a key inventor and research leader for the PD-L1 immunotherapy atezolizumab (Tecentriq).
Dr. Irving received his Ph.D in Immunology from the University of California, San Francisco, and a B.A. in Physiology from the University of California, Berkeley. His doctoral work, performed in the laboratory of Dr. Arthur Weiss, pioneered the single-chain chimeric antigen receptor (CAR) technology. He performed post-doctoral work at Harvard and UCSF on early T cell development. His work has been published in top tier journals including Cell, Science, Cancer Cell, Nature Immunology, and Immunity, and he is an inventor on patents that include the single-chain CARs and atezolizumab. Dr Irving is also a musician and studied clarinet performance at the Eastman School of Music at the University of Rochester, NY.
Anne Keane, J.D. is the Senior Vice President of Regulatory and Quality. Anne is an experienced regulatory leader with extensive experience across numerous therapeutic areas and phases of development. She has contributed to more than 20 development programs at both small and large companies including Lyell, Achaogen, Genentech, Merck KGaA, Jazz and Arginox Pharmaceuticals. Prior to joining Amunix, Anne served as the Vice President of Regulatory Lyell Immunopharma, where she had the opportunity to lead the drafting of a Friends of Cancer White Paper: Designing the Future of Cell Therapies, which proposed a number of opportunities to accelerate early cell therapy research. While at Achaogen, Anne led the regulatory and clinical quality organizations through the development and approval of Zemdri®, an important new antibiotic for gram negative infections. Earlier experience includes leading successful regulatory filings for Avastin® and Perjeta®.
Anne received a law degree from the University of Washington Law School and a Physician Assistant Degree from the Albany Medical College Physician Assistant program.
Zeeshan Merchant serves as Chief Financial Officer of Amunix. Mr. Merchant has over 15 years of experience in biotechnology as an investment banker and investor. Prior to joining Amunix, Mr. Merchant worked as an investment banker at Morgan Stanley, serving as an Executive Director in the firm's healthcare investment banking group. In this role, Mr. Merchant advised U.S. and Asia based biotechnology companies on financings and strategic matters, and successfully executed over 50 transactions, including $20 billion in financing and $25 billion in mergers and acquisitions. Prior to Morgan Stanley, Mr. Merchant worked as Senior Analyst at Ayer Capital, a healthcare dedicated investment fund. In this role, Mr. Merchant identified and analyzed biotechnology and healthcare investments globally. Prior to Ayer Capital, Mr. Merchant worked as a private equity Associate at TA Associates, a leading, global growth private equity firm.
Mr. Merchant received a B.A. in Economics from the University of Pennsylvania.
Dr. Mootz is the Chief Business Officer of Amunix. Before joining the company, she was an independent consultant working with VCs and pharmaceutical companies on a wide range of corporate development and strategy projects, including new company formation, product launch strategy, and M&A strategy. Prior to that, she served as Chief Business Officer of ORIC Pharmaceuticals, where she had a broad role spanning corporate development and a variety of operational functions. While VP of Corporate Development at Achaogen, she helped the company complete a successful IPO, led the project team for the company's lead Phase 3 antibiotic (now launched as ZEMDRI), and helped raise over $200M in capital. Earlier experiences include playing key roles in a successful M&A while at BiPar Sciences, and in a successful new indication launch for Avastin while at Genentech.
Dr. Mootz started her career in industry at L.E.K. Consulting, where she worked with biotechnology and pharmaceutical companies on a wide range of projects. She earned a B.S. in Biology from Duke University and a Ph.D. in Biochemistry from Harvard University.
Dr. Volker Schellenberger is a co-founder of Amunix and currently serves as President and Chief Technology Officer. Dr. Schellenberger has extensive industry experience in protein engineering and drug discovery. Previously, he headed the Protein Engineering department at Genencor, where he invented combinatorial consensus mutagenesis, selection by micro-compartmentalization, as well as mutator technology. In addition, he initiated and led collaborations with Seattle Genetics that focused on antibody-enzyme fusion proteins. Prior to his work on biotherapeutics, Dr. Schellenberger directed projects optimizing enzymes for industrial applications as well as microbes for metabolic pathway engineering.
Dr. Schellenberger received his Ph.D. from Leipzig University, where he studied protease catalyzed peptide synthesis. After postdoctoral studies at the Institute for Protein Research in Pushchino (Russia), he moved to the University of Göttingen where he developed a novel method for the production of peptides from recombinant peptide-multimers. After a postdoctoral fellowship with Bill Rutter at the University of California, San Francisco, Dr. Schellenberger joined Genencor in 1994. Dr. Schellenberger is the author of over 40 scientific papers and an inventor on more than 70 issued and pending patent applications. He is also the recipient of the Karl Lohmann award of the German Society of Biochemists.
Angie serves as Chief Executive Officer of Amunix Pharmaceuticals Inc. Prior to joining Amunix, Dr. You served as Chief Business & Strategy Officer and Head of Commercial at Sierra Oncology (NASDAQ: SRRA), a publicly listed hematology and oncology drug development company, where she helped the company through a successful initial public offering. She also led the company's strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets. Prior to Sierra, Dr. You served as Chief Business Officer of Aragon Pharmaceuticals, a private oncology drug discovery and development company, where she was responsible for finance, operations, human resources, and business development. At Aragon, Dr. You helped secure several rounds of financing as well as leading the business development process that resulted in the company's acquisition by Johnson & Johnson. In previous roles, Dr. You served as Chief Business Officer at Synosia Therapeutics and Ren Pharmaceuticals. Before joining Ren Pharmaceuticals, Dr. You focused on new company formation at Venrock Ventures. In addition, Dr. You currently serves on the board of directors of ORIC Pharmaceuticals.
Dr. You earned a Ph.D. in Biochemistry from Harvard University and a B.A. in Chemistry from Harvard College.
Nicky Barber serves as the Vice President of Finance at Amunix. She is a skilled finance executive with over 20 years of experience guiding financial strategy and managing the accounting function for both private and publicly traded companies in the life sciences and medical tech industry. Prior to joining Amunix, Ms. Barber was Corporate Controller at Invuity Inc., where she oversaw the accounting team and worked with the C-Suite to ensure SEC/SOX compliance as a public company. As an integral part of the Invuity diligence team in the company's acquisition by Stryker, she oversaw the transition of the accounting function as well as determined the accounting and cash impact upon acquisition close. Prior to Invuity, Ms. Barber was the Corporate Controller at Singulex where she was responsible for accounting and general administration, as well as preparation of IPO-related filings. In addition to these roles, Ms. Barber worked at Chemocentryx and at Exelixis in various accounting functions where her roles and responsibilities included SEC/SOX oversight, financial oversight of clinical trials, payroll, equity, and taxes. Ms. Barber received a B.A. in Biopsychology from Vassar College and is an active California Certified Public Accountant.
Katherine Bock has approximately 20 years of experience in the healthcare industry, including positions of increasing responsibility in finance/investor relations, communications, corporate strategy, corporate development and research. She most recently served as Head of Investor Relations & Corporate Strategy at Arcus Biosciences where she executed on the company's successful $348 million financing in May of 2020 and navigated investors, as well as sell-side analysts, through deal economics and announcement of the company's 10-year partnership with Gilead to develop next-generation cancer immunotherapies. Previously Katherine Bock led Corporate Development & Investor Relations at Nevro, a medical device company focused on neuromodulation. During her tenure, she held various roles which included taking the company public on the NYSE in 2014, as the first medical device company to price above their range since 2007. She also helped lead subsequent financings, including the largest medtech follow-on in at least 10 years and a convertible raise of $172.5 million. Katherine was also an Associate in Lazard's Healthcare Investment Banking Group where she focused primarily on M&A advisory roles and capital market transactions. She has held additional positions at Adverum Biotechnologies, Genentech (a Member of the Roche Group) and Corgentech. Katherine has over 5 years of biotech research experience including positions in the small molecule Translational Oncology Group at Genentech and the Oncology Group at Corgentech.
Katherine received her M.B.A. from The Wharton School at the University of Pennsylvania in 2009 and received her B.S. in Applied Mathematics at San Francisco State University in 2002.
Katherine has also been active in the community with the Board of the Northern California Chapter of the National Multiple Sclerosis Society as the former Treasurer.
Michelle Heath serves as the Head of People at Amunix. She has over 20 years of experience in both strategic and hands-on HR leadership in the biotechnology and non-profit sectors, including companies such as Christine Mathews Consulting, CytomX Therapeutics, Monogram Biosciences, Codexis, R2 Technology and BUILD. She brings extensive experience working in companies during high growth periods. Leveraging her collaborative and creative approach to HR, she has been responsible for building and managing systems, processes, and resources to support high performing teams and overall business strategy. Michelle holds a B.A. in Psychology from the University of California at Santa Barbara.
Robert Jones serves as the Vice President of Contracts at Amunix. He brings over 18 years of extensive contract negotiation experience in both small and large companies, including Sierra Oncology, Pharmacyclics, Gilead, and Abbott Vascular. Before joining Amunix, Robert served as Senior Director of Contracts at Sierra Oncology, where he negotiated manufacturing, collaboration, and clinical supply agreements, and managed CRO contract-related issues. He was also responsible for all domestic and international clinical trial contracts, as well as informed consent form reviews. Prior to Sierra Oncology, Robert worked at Pharmacylics, where he led the Contracts Management team through the development and approval of Imbruvica (ibrutinib), developed the infrastructure between Contracts Management and Finance, and provided leadership on budgeting, contract negotiation, and outside counsel management across functions.
Robert attended Clarendon College and Phoenix College.
Ursula McCurry serves as the Vice President of Clinical Operations at Amunix. Ursula is a seasoned clinical operations leader with over 20 years of global clinical development experience across a number of established and emerging biotech and pharmaceutical companies including Genentech, Exelixis, Astex, and QLT Inc. She has led global clinical operations programs spanning a variety of therapeutic areas and all phases of clinical development, contributing to over 20 programs and subsequent multiple regulatory approvals at both small and large biotech companies. She also brings significant partnership and alliance management experience. Prior to joining Amunix, Ursula served as Clinical Program Director at Genentech, leading multiple programs from entry into the clinic into phase three development, including taselisib and GDC-9545. She has also served as part of Drug Safety teams, ensuring quality, compliance, pharmacovigilance, and safety reporting.
Ursula received a Master of Arts degree from Simon Fraser University and a certificate in Biotechnology, Clinical Trial Design and Management from San Francisco State University.
Dr. Nabeela Rasheed serves as the Vice President for Intellectual Property at Amunix. Before joining Amunix, Dr. Rasheed served as Section Head of Intellectual Property at AbbVie, where she devoted her time to building and securing intellectual property portfolios in therapeutic areas including immunology, oncology, antiviral, women's health, renal disease, and neuroscience. Prior to that, she spent 20 years working at a law firm specifically focused on intellectual property law as it applies to the biopharmaceutical industry, as well as advising clients on related regulatory and legislative changes in fast-evolving legal markets. She has been integrally involved in implementing strategic plans and launches of several pharmaceutical products.
Dr. Rasheed is a member of the State Bar of Illinois, holds a Ph.D. in Biochemistry from the University of Liverpool, United Kingdom, and a Juris Doctorate Degree from Chicago Kent College of Law.
Dr. Geetha Shankar serves as the Vice President of Clinical Science and Clinical Operations at Amunix. She has over 25 years of experience in drug discovery and development, with expertise extending from high throughput screening and drug discovery, to clinical development (IND to phase III), regulatory filings, and market access. Before joining Amunix, Dr. Shankar spent 10 years at Genentech as Group Clinical Science Director. In this capacity she oversaw US, EU, and global approvals of Tecentriq® in non-small cell lung cancer. She was also a key contributor on the PI3K program and worked in both breast and lung cancer indications on proof-of-concept studies. Prior to Genentech, she worked at Exelixis for six years, first as a team leader on drug discovery projects, and later transitioning to clinical development. In the latter function, she worked on early trials for cabozantinib in medullary thyroid cancer. Prior to Exelixis, she worked at Ceretek LLC, an oncology startup focused on lipid G-protein coupled receptors.
Dr. Shankar received a Ph.D. in Molecular Pharmacology from Northwestern University School of Medicine and an M.S. in Medicinal Chemistry from the University of the Sciences in Philadelphia. She also holds a B.Pharm. from the College of Pharmacy in Bangalore, India.
Dr. Taniguchi serves as the Vice President of Bioanalytical Sciences at Amunix. He has over 25 years of experience in biopharmaceutical drug development from pre-IND to post-marketing in the areas of oncology, inflammation, and rare diseases like MPS and PKU. Gary has strategic and scientific expertise in the areas of CMC analytical and bioanalytical, which includes analytical characterization and comparability and PK, immunogenicity and PD biomarker development. Prior to joining Amunix, he has led analytical, bioanalytical, and/or Quality groups at various companies including Coherus BioSciences, BioMarin, Genentech, Abbott, and PDL BioPharma/Facet Biotech (now part of Abbvie). While at Genentech and BioMarin, Dr. Taniguchi along with other biopharmaceutical industry scientists wrote the early manuscripts for strategies in detecting and characterizing the immunogenicity of biotherapeutics.
Dr. Taniguchi received his Ph.D. in Pharmaceutical Chemistry majoring in Biochemistry and Molecular Biology from the University of California at San Francisco.
Jamie Brush, M.D.
Frazier Healthcare Partners
Rich Heyman, Ph.D.
Chairman of the Board of Directors
David Hirsch, M.D., Ph.D.
Longitude Capital
Ciara Kennedy, Ph.D., M.B.A.
Trisha Millican
Chief Financial Officer, Metacrine
Otello Stampacchia, Ph.D.
Omega Funds
James N. Topper, M.D., Ph.D.
Frank Watanabe
Chief Executive Officer, Arcutis
Jamie Brush, M.D., is a General Partner and Portfolio Manager on the Frazier Life Sciences team. Jamie co-leads the Frazier Life Sciences Public Fund (FLSPF) with Albert Cha and serves as a co-Portfolio Manager for the FLSPF. Jamie led Frazier's public investments in Trillium Therapeutics (NASDAQ: TRIL; acquired by Pfizer), Translate Bio (Nasdaq: TBIO; acquired by Sanofi Pasteur), Iveric Bio (Nasdaq: ISEE), Rocket Pharmaceuticals (Nasdaq: RCKT), Krystal Biotech (Nasdaq: KRYS), and co-led Frazier's investments in ARMO (Nasdaq: ARMO; acquired by Eli Lilly), and Ignyta (Nasdaq: RXDX; acquired by Roche).
Prior to joining Frazier, Jamie was a management consultant with the Boston Consulting Group, where he was a core member of the Healthcare Practice. In this capacity, he led projects involving Biotechnology mergers and acquisitions, R&D, manufacturing, and business development strategy. Jamie received his M.D. from the University of Southern California, where he was inducted into the Alpha Omega Alpha honors society, and his B.A. from Middlebury College. He completed his post-graduate training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Rich Heyman is an accomplished scientist and biopharma executive with over 25 years of experience leading innovative biotechnology companies. Dr. Heyman previously served as Chief Executive Officer of Seragon Pharmaceuticals, a company focused on drugs targeting hormone dependent cancers, until its acquisition by Roche in 2014. Dr. Heyman was also the co-founder and Chief Executive Officer of Aragon Pharmaceuticals, which was acquired by Johnson & Johnson in 2013. Prior to Aragon, Dr. Heyman held leading scientific and business roles at several biotechnology companies, including X-Ceptor Therapeutics and Ligand Pharmaceuticals. At Ligand, Dr. Heyman led the development of Panretin® and Targretin®, which were approved by the FDA for the treatment of cancer.
In addition to serving on the Amunix Pharmaceuticals Board of Directors, Dr. Heyman is a Director at Gritstone Oncology, Yumanity Therapeutics, Metacrine Inc., Vividion Therapeutics, Mavupharma, and ORIC Pharmaceuticals. He is also the Vice Chairman of The Salk Institute and author or inventor of more than 120 publications and patents.
Dr. Heyman was an NIH postdoctoral fellow at the Salk Institute and received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.
Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Ventures, where he worked in the life sciences practice. Prior to Pequot Ventures, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company.
Dr. Hirsch currently serves on the boards of Collegium Pharmaceutical (NASDAQ: COLL), Inflazome, Molecular Templates (NASDAQ: MTEM), Poseida Therapeutics, Rapid Micro Biosystems, Tricida (NASDAQ: TCDA) and Velicept. Previous boards include Civitas Therapeutics (acquired by Acorda), Precision Therapeutics and Zavante Therapeutics (acquired by Nabriva). Dr. Hirsch also led Longitude Capital's investments in Amarin (NASDAQ: AMRN) and Cadence Pharmaceuticals (NASDAQ: CADX).
Dr. Hirsch holds a Ph.D. in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a B.A. in Biology from The Johns Hopkins University.
Ciara Kennedy served as President and Chief Executive Officer of Amplyx Pharmaceuticals from 2016 until its acquisition by Pfizer in 2021. Dr. Kennedy has a proven track record of delivering significant results and advancing therapeutic and diagnostic programs across multiple therapeutic areas and stages of development in the biotech industry. Amplyx has successfully raised over $140M to develop novel treatments for immunocompromised patients. Dr. Kennedy has successfully in-licensed, and advanced into Phase 2 studies, programs to address a variety of life-threatening conditions. Dr. Kennedy is also a founder of Reneo Pharmaceuticals and Mirum Pharmaceuticals. Dr. Kennedy serves as an independent Board member of, privately held, Aristea Therapeutics. Prior to Amplyx, Dr. Kennedy served as Chief Operating Officer at Lumena Pharmaceuticals, until the company's acquisition by Shire Pharmaceuticals in 2014 and as Vice President, Head of Cholestatic Liver Disease at Shire post acquisition. As COO of Lumena, Dr. Kennedy played a critical role in the development of assets licensed from Pfizer and Sanofi, financing the company and preparing to take the company public. Prior to Lumena, Dr. Kennedy held several positions at Cypress Bioscience Inc. where she played a key role in the company's FDA approval and launch of Savella® for Fibromyalgia, corporate acquisitions and the in-licensing of several clinical assets. Prior to joining Cypress Bioscience, Dr. Kennedy held several positions in the Program and Alliance department of Biogen Idec, managing multiple projects spanning the drug discovery and development continuum. A Ph.D. scientist by training Dr. Kennedy received her doctorate at the Queen's University of Belfast, Northern Ireland. In 2004 Dr. Kennedy became a member of the inaugural class of the Rady School of Management at UCSD and graduated with a Master of Business Administration in 2006.
Trisha Millican has 20 years of leadership experience in the life science industry encompassing debt and equity financings, mergers and acquisitions, licensing transactions, co-development and promotional arrangements, and commercial product launches. She is currently the Chief Financial Officer of Metacrine. Prior to Metacrine, Ms. Millican was the Senior Vice President of Finance at Seragon, a private biotechnology company focused on developing Selective Estrogen Receptor Degraders (SERDs) targeting hormone dependent cancers, which was acquired by Genentech. Prior to Seragon, she served as Vice President of Finance at Aragon, a discovery-stage small molecule company focused on therapeutics for the treatment of hormone- resistant cancers, which was acquired by Johnson and Johnson. Prior to Aragon, Ms. Millican worked in various senior financial management roles at Zogenix, a pharmaceutical company developing and commercializing innovative central nervous system therapies for people living with serious and life- threatening rare central nervous system disorders and medical conditions. Ms. Millican spent five years with the public accounting firm Deloitte LLP. She holds a B.S. in Accountancy from the University of San Diego and is a certified public accountant in the state of California.
Otello founded Omega Funds in 2004 and leads the firm's investor relations and strategic initiatives. He is a member of the firm's investment committee and is also heavily involved in a number of Omega's therapeutic areas of interest, particularly in oncology, rare diseases and inflammatory disorders.
Previously, Otello was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. Before AlpInvest, he was the portfolio manager of the Lombard Odier Immunology Fund, a $3 billion listed investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and New York offices). Before Goldman, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.
Jamie is a Managing General Partner of Frazier Healthcare Partners' Life Sciences team. Since joining Frazier in 2003, he has led and served as a board member for a number of Frazier's successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Calistoga Pharmaceuticals (co-founder, sold to Gilead Sciences), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), CoTherix (sold to Actelion), and Threshold (NASDAQ: THLD). He currently represents Frazier on the boards of Alcresta Therapeutics, Allena Pharmaceuticals (NASDAQ: ALNA), Alpine Immune Sciences (NASDAQ: ALPN), AnaptysBio (NASDAQ: ANAB), Aptinyx (NASDAQ: APTX), Entasis Therapeutics (NASDAQ: ETTX), and Mavupharma. He is also a board observer for Sojournix.
Prior to joining Frazier, Jamie was the head of cardiovascular R&D at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the medical school faculties at Stanford and Harvard Medical School prior to joining COR.
Jamie received his M.D. and Ph.D. in Biophysics from Stanford and holds a B.S. from the University of Michigan. He did his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford.
Frank Watanabe is the President, CEO and Director of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a late-stage dermatology biotech company. Mr. Watanabe has extensive experience across general management, marketing, sales management and business development in US, international and global markets. Under his leadership, Arcutis has raised more than $700M in private and public financings, and has advanced multiple novel therapies from bench through the clinic, with a first FDA regulatory filing expected in 2021. Prior to joining Arcutis, he was co-founder and Chief Operating Officer of Kanan Therapeutics, a cardiovascular drug development company, and before that, was Vice President of Strategy and Corporate Development at Kythera Biopharmaceuticals. Earlier in his career, he was an executive at Amgen, Inc., where he was involved in the development of Repatha® for hyperlipidemia and Aimovig® for migraine. Previously, he was an executive with Eli Lilly and company, and an official in the U.S. Government. He was also a commissioned officer in the U.S. Navy Reserves for 25 years. Mr. Watanabe earned his M.A. in National Security Studies, and his B.A. in International Relations, both at Georgetown University.
David Chang, M.D., Ph.D.
Fred Ramsdell, Ph.D.
David Chang, M.D., Ph.D., is the President, Chief Executive Officer and Co-Founder of Allogene. He previously served as Executive Vice President, Research & Development, and Chief Medical Officer of Kite, a Gilead Company. He has an industry-leading track record of innovation in the field of oncology drug development, including the development of YescartaTM (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma. From 2002 to 2014, he held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology. During this time, David spearheaded personalized therapy strategies underlying the success of Vectibix® (panitumumab). He also provided therapeutic area leadership to pivotal programs for Blincyto® (blinatumomab), a bispecific T cell engager antibody in acute lymphocytic leukemia and for IMLYGICTM (talimogene laherparepvec), a first-of-its-kind oncolytic immunotherapy in melanoma. Prior to joining Amgen, David held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He obtained a B.S. in biology from the Massachusetts Institute of Technology and MD and PhD degrees from Stanford University. David completed an internship and residency in internal medicine at Brigham and Women's Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow.
Fred Ramsdell, Ph.D., is a veteran biotechnology leader in immunology with nearly three decades of experience and a founder of Sonoma Biotherapeutics where he serves as CSO. Immediately prior to Sonoma, he served as CSO of the Parker Institute for Cancer Immunotherapy where he helped build and advance the research portfolio from the inception of the institute and remains an advisor.
After a fellowship at the NIH, Fred joined Immunex, studying T-cell activation and tolerance, with a focus on gene discovery and characterization. He later joined Darwin Molecular (acquired by Celltech R&D), to establish the immunology program. There, he led the team that discovered and characterized FoxP3, a gene critical to the function of regulatory T-cells (and the award of the Crafoord Prize in 2017). Fred joined ZymoGenetics in 2004, where he led teams studying novel proteins with potential regulatory activity in lymphoid cells. In 2008, Fred helped to build Novo Nordisk's Inflammation Research Center in Seattle.
He earned his doctoral degree in microbiology and immunology from the University of California, Los Angeles and holds a bachelor's degree in biochemistry and cell biology from the University of California, San Diego.
Our Investors
About Amunix
Pro-XTEN
T Cell Engagers: XPATs
Cytokines: XPACs
Amunix Pharmaceuticals, Inc.
2 Tower Pl #1100,
© 2021 Amunix Pharmaceuticals, Inc. All rights reserved.
Website Design: Hane Chow, Inc.


text:
Q: Use Wordpress or another CMS within a web application? Apologies for the broad question, but I don't know where to start. I have a php web application for members with various functions and features. On the dashboard, I need to implement some dynamic news - the kind of news that that non-developer can write and publish without any interference with the source code.
Can I implement Wordpress into my existing app so that authors can login, write then publish so that my dashboard can display the latest posts?
At its most basic level, I'm thinking:

*

*a new subfolder for Wordpress with its own separate database.

*a plugin to display the latest posts content only

*an iframe on my dashboard to display the output of that plugin

But all that seems like a very hacky workaround. Is there a more native way of doing this? Or is there another CMS library that could achieve the same result?

A: I have a solution that I am running with. It's a separate Wordpress site with the latest posts accessed via the built-in API (https://developer.wordpress.org/rest-api/reference/posts/)
I will be getting all the posts in a category with:
curl https://example.com/wp-json/wp/v2/posts

Then storing the posts in array before looping through that array to display the title and content on my dashboard with:
curl https://example.com/wp-json/wp/v2/posts/<id>

where <id> is from the first call.
This is clean, native and serves the exact purpose I need. The member info, while secured doesn't need to be top-secret, so we're just using the Wordpress password-protection with the same password for all posts so as long as the API calls are server-side with https, the security works too :)

A: Looks like you want Dynamic News Feature in your existing PHP Web Application.
And you want to build that specific feature in Wordpress.
I don't think it's a good idea to use Wordpress CMS for small features like this.
IF you already have full functional PHP Web Application then I would recommend to use same Web Application to build Dynamic News Feature which will allow users on the site to post.
I don't think that's very complex.
IF you want to get into Wordpress ecosystem then you will need to convert your PHP Web Application into Wordpress and then you can build additional functionality.
I think that's the ideal way to go. Let me know if more questions. Thanks.

redpajama_set_name: RedPajamaStackExchange


text:
Olenecamptus beardsleyi is a species of beetle in the family Cerambycidae. It was described by Gressitt in 1956.

References

Dorcaschematini
Beetles described in 1956

redpajama_set_name: RedPajamaWikipedia


text:
Kəpənəkçi (also, Kapanakchi) is a village in the Goranboy Rayon of Azerbaijan.

References

Populated places in Goranboy District


text:
The National Geographic Magazine, Volume 3
Feldspar is sparingly present, and includes both monoclinic and triclinic forms, whose crystallographic boundaries are invariably lacking.
Treatment of the sand with dilute acid produces effervescence, which is not due to incrustations of sodium carbonate. By persistent search among particles separated in a heavy solution, a few grains were discovered which, from their complete solubility with offervescence in very dilute acid, as well as their optical properties, left no doubt as to their being calcite.
The mica group has only one representative, biotite, and this occurs most sparingly. Though much of the sand was examined, but few fragments were found. Its foliated character renders it easily transported by water and explains its absence from among the heavy minerals.
Shaly, slaty and schistose material forms the major part of the coarser grains. Thin sections from the largest pieces plainly indicated hornblende schist.
A region of glaciers would seem to be favorable not only to the collertion of meteoric material, but also to the destruction of the country rocks, the setting free of their mineralogic constituents in a comparatively fresh state, and their transportation to the sea. It was hoped that this sand would yield some of the rarer varieties of minerals, but tests for native iron, platinum, chromite, gneiss, and the titaniferous minerals proved ineffectual. Titanium is present, but in such small quantities that it could only be detected by means of hydrogen peroxide. The use of acid supersulphate and the borotungstate of calcium test of Lasaulx failed to reveal the presence of native iron.
It will be seen from the foregoing enumeration that the sand is made up of grains of gold, magnetite, garnet, hornblende, pyroxene, zircon, quartz, feldspar, calcite and mica, associated with fragments of a shaly, slaty and schistose character. While the information at hand is hardly sufficient to warrant much speculation concerning the rock masses of the interior, still there is no doubt that the sand is derived from the destruction of metamorphic rocks.
REPORT ON FOSSIL PLANTS.
BY LESTER F. WIRD.
DEPARTMENT OF THE INTERIOR,
UNITED STATES GEOLOGICAL SURVEY,
Washington, D. ('., Varch 12, 1891. Mr. I. C. RusSELL,
United States Geological Surrey. My Dear Sir: The following report upon the small collection of fossil plants made by you at Pinnacle pass, near Mount St. Elias, Alaska, and sent to this division for identification has been prepared by Professor F. H. Knowlton, who gave the collection a careful stuly during my absence in Florida. Previous to going away I had somewhat hastily exaniined the specimens and seen that they consisted chiefly of the genus Salid, some of them reminding me strongly of living species. I have no doubt that Professor Knowlton's more thorough comparisons can be relied upon with as much confidence as the nature of the collection will permit, and I also agree with his conclusions.
"The collection consists of seven small hand specimens, upon which are impressed no less than seventeen more or less completely preserved dicotyledonous leaves.
"These specimens at first sight seem to represent six or eight species, but after a careful study I think I am safe in reducing the number to four, as several of the impressions have been nearly obliterated by prolonged exposure and cannot be studied with much satisfaction.
" The four determinable species belong, without much doubt, to the genus Salir. Number 1, of which there is but a single specimen, I have identified with Salix californica, Lesquereux, from the auriferous gravel deposits of the Sierra Nevada in California.* The finer nervation of the specimens from the auriferous gravels is not clearly shown in Lesquereux's figures, nor is it well preserved in the Mount St. Elias specimens; but the size, outline, and primary nervation are identical.
"Number 2, of which there are six or eight specimens, may be compared with Salix racana, Heer,f a species that was first described from Greenland and was later detected by Lesquereux in a collection from (ooks inlet, Alaska. The Mount St. Elias specimens are not very much like the original figures of Heer, but are very similar, in outline at least, to this species as figured by Lesquereux. They are also very similar to
* Mem. Mus. Comp. Zool., vol. VI, no. 2, 1878, p. 10, pl. i, figs. 18-21. | Flor. focs. Arct., vol. I, 1868, p. 102, pl. iv, figs. 11-13; pl. xlvii, fig. 11.
Proc. Nat. Mus., vol. V, 1882, p. 447. è loc. cit., pl. viii, fig. 6.
some forms of the living S. rostrata, Richardson, with entire leaves. It is clearly a willow, but closer identification must remain for more complete material.
" Number 3, represented by four or five specimens, is broadly elliptical in outline, and is also clearly a Salir. It is unlike any fossil form with which I am fimiliar, but is very similar to the living I. nigricans, For., var. rotundifolia, and to certain forms of S. silesiaca, Willd. The nervation is very distinctly preserved, and has all the characters of a willow leaf.
"Number 4, represented by three or four very fine specimens, is a very large leaf, measuring 1:3 cm. in length and 3 cm in width at the broadlest point. It may be compared with Sulir macrophylla, Heer,* but it cannot be this species. It is also like some of the living forms of S. nigra, Marsh., from which it cliffers in having perfectly entire margins.
"While it is manifestly impossible, on the basis of the above identifications, to speak with confidence as to the age or formation containing these leaves, it can hardly be older than the Miocene, and from its strong resemblance to the present existing flora of Alaska it is likely to be much younger." [F. II knowlton.] Very sincerely yours,
LESTER F. WARD.
* Tert. Fl. Helv., vol. II, 1836, p. 29, pl. Ixvii, fig. 4.
Puge.
Admiraliy bay..
Agassiz glacier, Ascent of...
- named....
Age of St. Elias range....
Alpenstocks, Necessity for ......... 165
Alpine glaciers..
Alton, Edmund, Contributions to ex-
ploration fund by.....
Archangelica, Mention of..
Atrevida (The), Mention of...
Arevida glacier....
Auriferous sands....
Avalanches....
Desengaño bay, named by Malaspina.. 63
Digges' sound, named by Vancouver... 68
Diller, J. S., Contribution to explora-
tion fund by......
Dip at Pinnacle pass......
Discovery (The), Mention of...
Disenchantment bay, Canoe trip in..96, 103
-- last view of.....
mention of...
visited by Malaspinit.
Dixon, Captain George, Explorations
of..
De Monti bay, Arrival at.
Descubierta (The), Mention of....
Devil's club (Panax horridum), Men-
tion of.....
Dobbins, J. W., Contribution to explo:
ration fund by
Dome pass, named.
Doney, L. S., Member of expedition... 76
Work of.......
Douglass, Colonel, Explorations of...... 62
Dry bay, Mention of.........
Farenholt, Lieutenant Commander 0.
F., Commander of U.S.S. Pinta..... 79
Faulted pebble from Pinnacle pass., 171, 172
Faults...
Thrusi, in Hitchcock range.
Floral hills, brief account of...
- pasy, brief account of......... 105, 108, 110
Formations of the St. Elias region...... 167
Fossils at Pinnacle pass...
description of Yakutat system... 172
Fossil plants, Report on, by Lester F.
Ward.......
Baie de Monti...
- named by La Pérouse
Baker, Marcus, Explorations by...... 70, 72
reference to biliography by.
Base Line, Measurement of
Bear, Meeting with......
Belcher, Sir Edward, Explorations
by.....
Bell, A. Graham, Contribution to ex-
ploration fund by
Bell, Charles J., Contribution to ex-
ploration fund by....
Bering bay, Mention of......
Bering, Vitus, Explorations by..... 58
Bien, Morris, Coniribution to explora-
tion fund by..
Birnie, Jr., Rogers, Contribution to ex-
Black glacier, Brief acccount of... 101, 104
Blossom island, Description of ...... 113, 122
Boussin, Henry. Mention of
Broka, George, Explorations by...... 73, 74
Camp hands.
Carpenter, 2 T., Contribution to ex-
Carroll, Colonel James.
Cascade glacier named...
Chaix hills named..
Chariot, The, Mention of...
Chatham, Mention of
Cherikof, Alexei, Explorations of....... 58
Christie, J. H., Member of expedition.. 76
Work of................ 82, 83, 84, 96, 103, 112,
Clover, Richardson, Contribution to
exploration fund by.....
Cook, Colonel James, Explorations of.. 58
Corwin (The) in Disenchantment bay.. 100
-- Return of
Crevasses.
- at Pinnacle pass..
Cross sound, visited by Vancouver's
expedition..
Crumbach, .. H., Member of expedi-
- Work of.....
Dagelet, M., Mention of..
Dail, W. H., Explorations by..
....... 70, 72
- reference to bibliography by.......... 58
Dalton, John, glacier named for.. 98
- mention of......
Definition of formations in St. Elias
region......
Gabbro on the Marvine glacier
Galiano, Don Dionisio Alcala, mention
Galiano glacier, Visit to.
Gannett, Henry, Contribution to ex-
Instructions from
Geology of the St. Elias region... 167
Geological Survey, Instructions from... 192
193, 19+
Gilbert, G. K., Instructions from... 192, 19:3
Glacial currents..
-- river, best example of.......
streams....
Glacier bay, mention of...
Glaciers in Disenchantment bay in
observed by Malaspina..... 64, 65
Puget...
of the St. Elias region......
- west of Icy bay......
Greely, A. W: Contribution to explora-
tion fund by.....
Guides, use of in ascending St. Elias... 166
Guyot glacier named.
Haerke, D. Tadeo, Haenke island
named for.....
island, Condition of, when seen by
Malaspina..... ........... 63, 64, 65, 97
visit to...........
Hayden, Dr. F. V., glacier named for... 108
Hayden, Everett, Contributions to ex-
Hayden glacier, Brief account of.. 108
Hays, J. W., Contribution to explora:
Height and position of St. Elias..... 189, 190
Hendricksen, Reverend Carl J., men-
tion of...
SO, 83
Hitchcock, Professor Edward, range
named for...
range, brief account of
from Pinnacle pass..
structure of..
Hooper, Captain C. L., Navigation of
Disenchantment bay..
Hosmer, E. S., Contribution to explo-
ration fund by,
- return of...
volunteer assistant...
Hubbarit, Gardiner G, Contribution to
exploration fund hy.
-, glacier named for.....
Hubbard glacier, brief description of.. 99
Malaspina glacier, character of............ 187
described and pamed..
--, excursion on....
from Blossom island.
mention of.....
Maldonado, reference to......
Marvine, A. R., Glacier named for... 112
Marvine glacier, Account of... 112, 122, 124
McCarteney, C. M., Contribution to ex-
ploration fund by.......
Mirage in Yakutat bay
Moraines
medial, on the Marvine glacier.. 123
on the Malaspina glacier....
near Yakutat bay........
Mount Augusta, avalanches on the
sides of....
elevation of..
Mount Bering, Height and condition
Mount Cook, Appearance of
- named..
- rocks composing
Mount Fairweather, height of..
Mount Logan, named.....
Mount Malaspina, Elevation of
named.
Mount Newton, named.
Mount St. Elias (see St. Elias, Mount).
Mount Vancouver, named.
Muir glacier, Visit to....
Mulgrave, Lord, Port Mulgrave named
for....
National Geographic Society, Instruc-
tions from
Névé fields....
Newton glacier, Ascent of...
Newton, Henry, Mountain named for.. 146
New York Times, Expedition of..... 172, 173
Nordhoff, Charles, Contribution to ex-
ploration fund by.........
Norris glacier, Mention of..
Nunatak in the Lucia glacier.............. 106
Oil stoves, Use of........
Orel, Mention of the...
Olkrytie, Mention of the......
Outfit necessary for Alaskan expedi-
Kerr, Mark B., Assiyned as an assist-
ant ..........
report ou topographic work ............ 195
Khantank island, village on ......
King, Harry, Contribution to explore-
Knapp, Hon. Lyman E., Mention of.... 79
Knight island, scenery near .......... 83
named by Piget.......
Knowlton, F. H., Report on fossil
plants...
L'Astrolabe, Mention of.
La Boussole, Mention of...
Lake Castani, Named...
Lakelets on the glaciers.........
Lakes, Abandoned heds of, near Blog-
som island
La Péronse, J. F. 8., Explorations of..58, 60
Leah, Boynton, Contribution to ex-
Libbey, Professor William, explora-
tions by..
Lindsley, W. Is., Member of expedi-
- Work of............ 122, 131, 134, 135, 139, 144
Lituya bay, mention of...
Logan, Sir W. E., Mountain named for.. 141
Lucia glacier, brief account of..
crossing of....... 105, 106, 108, 109
Lynn canal, mention of......
Panax horridum
Partridge, William, Member of expe.
dition...
Work of...
Piedmont glaciers, characteristics of... 122
example of....
type of glaciers, mention of........ 57
Pimpluna rocks, mention of............ 70, 187
Pinnacle pass clitfs, account ol...... 132, 137
---, height of..
- view from.
-, description of....
............. 130, 132
system, description of rocks of.. 167, 170
- named
Pinta, mention of the..
Phipps, C. J., Port Mulgrave named
Plants on Blossom island............ 114
Point Esperanza, Camp at........... 82, 84, 85
Glorious, named.
Riou, Mention of.
Port Mulgrave..
- named by Dixon..
Powell, J. W., Contribution to explora-
tion fund by...........
Malaspina,
of.......
Alejandro, Explorations

redpajama_set_name: RedPajamaCommonCrawl


A massive, unexpected wave of goodwill began online with a simple idea: "Imagine if we all committed 20 acts of kindness to honor the lost children of Newtown." NBC News National and International Correspondent Ann Curry sent the message on Twitter and Facebook. The idea has evolved into a viral effort known as "26 Acts of Kindness," in honor of the students and faculty who died at Sandy Hook Elementary.
Ann Curry's inspiration for #26Acts of Kindness dates back to an experience she had while reporting on the genocide in Darfur in 2007, and the joy that giving Polaroid pictures of children brought to mothers who had never held a photograph of their kids.
When I was tweeting, I noticed that the number one trending topic was something like "ThingsIlikeaboutmyself." I thought, "Well, if you do act of kindness, I bet you'll like even more about yourself." So that's what I tweeted.
Trouble viewing this on your device? Click here.


The Big Idea: In today's world, where geography doesn't matter, tribes are thriving. Tribes are about connection and caring. Leaders of tribes build connection and caring into the tribe.
Human beings need to belong.
You can't have a tribe without a leader, so learn about leadership.
Everyone is expected to lead.
Geography used to restrict the boundaries of tribes but the internet changed that.
Leadership is pulling, not pushing.
It's better to make the rules than to follow them.
Leadership is not management. Management is getting things done. Leadership is about creating change and inspiring people.
Leaders are not afraid of change.
Authority does not equal leadership.
Two things to turn a group into a tribe: shared interest, a way to communicate.
A leader of a tribe encourages members to communicate with each other.
Tribes aren't about stuff. They are about connections, in the context of a shared interest.
A crowd is a tribe without a leader and without communication.
An artist needs 1,000 true fans. A corporation needs more than 1,000 but fewer than it thinks. True fans are much more important than average customers.
Real leaders give back generously to their tribe and help the tribe grow closer.
Change is made by acting first and asking for forgiveness later.
The best followers are not blind sheep but vibrant fanatics.
One person with a persistent vision can make changes happen.
Industries don't die by surprise. The signals are always there.
Life is too short to be unhappy and mediocre.
Publish a manifesto, connect with followers, encourage followers to connect with each other.
It's powerful to exclude outsiders.
Be willing to be wrong. Being wrong isn't fatal.
The big win for nonprofits is turning donors into patrons and activists. Encourage donors to network and volunteer. And vice versa.
Caring is the emotion at the center of the tribe. Members of a tribe care about the tribe and each other.
The secret of effective leadership is to first listen deeply.
Success and change happen a little at a time. Drip, drip, drip. It takes time.
You can't bring permanent change in from the outside.
Real leaders don't care about who gets the credit. There's no record about Martin Luther King, Jr., or Gandhi whining about credit.
The Big Idea: The presence of cognitive biases means we don't always act rationally. Cialdini outlines six weapons of influence which can be used to influence behavior. Even if you aren't a salesperson, you are a consumer so it's good to be aware.
We tend to reciprocate a favor, even if it is unsolicited.
Start by asking for a large favor and then expect a concession to the real favor you want.
Selling down works better than selling up.
After making an initial choice, we tend to stand by that choice over time. People usually don't switch sides after they have committed.
In a debate, start with a small area of agreement or concession and build from there. People want to stay consistent.
We are more consistent in our commitment if we did it for our own purpose rather than from external reward or pressure.
Examples: canned laughter, tip jars, Jonestown, peer learning, bystander effect.
People want to please others whom they like.
Attractive people are more persuasive.
People like others who are similar to them.
Establish a connection between your product and an attractive or winning person.
We obey authority mindlessly in many cases.
Titles, uniforms, and appearances convey authority.
Losing something is more painful than gaining something.
Something that is hard to obtain is more valuable than something that is easier to obtain.
People fight fiercely to retain something they worked for.
Indifference towards a lover becomes passion when a rival appears.
Scarcity+rivalry drives up prices in bidding wars. Always mention a rival buyer when selling something.
The Big Idea: Follow the four seasons in your life. In the spring, you plant new seeds. In the summer, you work the land. In the fall, you harvest the crops. In the winter, you let the soil rest.
Don't be so ego-centric to think you can beat laws of nature and laws of physics.
We will all get older and die, so get moving today.
Starting a business is like having a child. The first year keeps you up at night. The second year is like the terrible two's. Eventually, your business will take care of you in your old age.
It took 50 years for Warren Buffett to become a billionaire (7 => 57), so start now.
Becoming a millionaire takes time.
Most entrepreneurs move around too much, stick with one thing.
It might take 10,000 hours to obtain mastery.
It might take 10 dark years to become a successful artist.
Follow the four seasons in your life.
Mass media shows us stories of successes (autumn) but never shows us stories of hard work (summer).
During the summer, work the land (plan and work).
During the autumn, harvest the crops (collect the rewards).
During the winter, let the soil rest (read and rest).
During the spring, plant seeds (experiment and test).
Long hours and hard work will be required during certain times in your life or business.
Don't forget to appreciate each season while you're there.
Tai Lopez is an entrepreneur, investor, and blogger who runs an awesome online book club. 67 Steps is a lecture series teaching how to be successful in health, wealth, love, and happiness.
The Big Idea: High potential people stumble in their careers most often because of a lack self-awareness of their own strengths and weaknesses. Fantastic advice in this book.
Many high performers are completely unaware of their weaknesses.
The book has specific advice and tools to help address weaknesses that could derail a career.
High performers: love learning, have high emotional intelligence, and have lots of perseverance.
Understand what motivates you and find the right job and organization for you.
Five key motivations: achievement, affiliation, power, autonomy, and purpose.
No one is going to care as much as you about your own development. Seek knowledge, feedback, and mentoring.


Movement of modifications in FortiWeb 5.6 Specialist certification exam has given birth to the top-ranked service like Fortinet NSE6_FWB-5.6.0 exam dumps 2019. Numerous NSE 6 Network Security Specialist professionals are trying to ace the NSE6_FWB-5.6.0 exam questions not even if of the stating that states "To survive in the IT field one need to have Fortinet NSE6_FWB-5.6.0 exam on its return to" yet also to obtain a name in the IT field. Every person knows that the intro of the NSE6 FWB 5.6.0 exam have widened the domain of IT. If one intends to keep himself upgraded, after that he needs to need to dive in the detailed globe of FortiWeb 5.6 Specialist exam.
Since you are in the search of the very best and also latest Fortinet NSE6_FWB-5.6.0 exam training material then you should have to inspect our NSE6_FWB-5.6.0 exam dumps 2019. As we all know that from years the preparation of Fortinet NSE6_FWB-5.6.0 exam questions have been done from guides or notes yet many thanks to us, we bring the transformation in the preparation of NSE6 FWB 5.6.0 exam questions by presenting the Fortinet NSE6_FWB-5.6.0 exam dumps questions Our NSE6_FWB-5.6.0 exam braindumps covers the entire FortiWeb 5.6 Specialist syllabus in a certain manner. Either you are a brand-new pupil of NSE6_FWB-5.6.0 exam questions or a specialist you can quickly understand the FortiWeb 5.6 Specialist exam dumps.
If you are planning to take the FortiWeb 5.6 Specialist new questions then you must keep the following points psychological while preparing for the NSE6_FWB-5.6.0 test. There are three types of NSE6_FWB-5.6.0 test students. Initially, that have prior knowledge regarding the NSE6_FWB-5.6.0 exam. Second who just prepare for Fortinet NSE6_FWB-5.6.0 exam questions and also hadn't done any practice. Third that simply take the NSE6_FWB-5.6.0 exam on a lighter note and also doesn't get ready for it. If you are among them after that you must seriously in the need of a finest as well as valid NSE6_FWB-5.6.0 exam preparation material.
TestCollections NSE6 FWB 5.6.0 braindumps have been made by the Fortinet professionals. These Fortinet professionals use their complete power of knowledge in order to facilitate you with the latest and valid NSE6_FWB-5.6.0 exam braindumps question. In addition to the context, we likewise offer you the NSE6_FWB-5.6.0 practice test. This NSE6_FWB-5.6.0 practice test will certainly help you in your self-examination regarding FortiWeb 5.6 Specialist test.
You can likewise download the free demo of the NSE6_FWB-5.6.0 practice test and also pdf dumps in order to have a much better suggestion of our exam training product. Last however not the least we also provide you the 100% passing guarantee with our NSE6_FWB-5.6.0 exam dumps. You can likewise get the 24/7 consumer treatment assistance on our NSE6_FWB-5.6.0 exam braindumps.


text:
ARTICLE | Composite Poles Help Expand Power Grid
Submitted by RS Technologies Inc. on Fri, 11/12/2021 - 13:18
By Laurie A. Shuster
As utilities seek to replace aging transmission and distribution poles and keep pace with new residential and commercial developments, some are turning to a potentially longer-lasting pole that also requires less maintenance. Composite poles, manufactured from fiber-reinforced polymers and polyurethane resins, are lighter and easier to transport than steel, concrete, or wooden poles. They are also more resistant to wildfire and, when treated with fire retardants, to fires that are wooden poles. And because the inspection, maintenance, and replacement of power poles represents significant costs for cash-strapped utilities, the higher initial costs of some composite poles can be more than offset by their durability in certain applications.
Scott Smith, the manager of apparatus engineering for Southern California Edison, of Rosemead, California, says his utility has deployed composite poles instead of wooden ones to support lines carrying 34,500 V or less, the voltage typically required for residential areas, in locations where wooden poles have unusually short service lives. "One of the places we use them is in the foothills, where we have a woodpecker problem," says Smith. "Woodpeckers can destroy a wood pole in just six months." Southern California Edison also uses the new poles in areas where termites are a problem; woodpeckers and termites generally cannot damage composite poles, Smith says. And because the poles are resistant to moisture, they are also useful in Southern California's coastal environment, he adds. What is more, composite poles are more likely to survive the region's infamous brush fire season than are wood poles, Smith says.
Michael Tenace, the technical director of RS Technologies Inc. a manufacturer of resin poles based in Calgary, Alberta, says that his firm's staff of civil engineers designed the poles, which are manufactured in modules of standard size that can be configured to build poles ranging in length from 30 to 120 ft. (9 to 30.5 m) and in diameter from 1 to 4 ft. (0.3 to 1.2 m). Although the firm's civil engineers can also assist utilities in designing soil amendments to help keep the poles in place in locations where the ground is less than suitable, most installations require no such intervention, he says. "There are no foundations necessary," says Tenace, who adds that "since it's a lighter structure than steel, wood, or concrete, you can often simply bore a hole, drop it in, and backfill."
Smith says that because the poles are lighter than those made with other materials, they are ideal for use in national forests, where the most environmentally benign method of delivery is by helicopter. Glen Barefoot, the corporate marketing manager for Strongwell, a firm based in Bristol, Virginia, that sells poles made of fiber-reinforced polymer, says that his company's 55 to 80 ft. (16.7 to 24.4 m) long one-piece poles weigh just a 10th as much as comparably sized concrete poles. Don Williams, the chief executive officer for Duratel, a Chicago-based firm that makes pultruded composite poles, says that a standard 40 ft. (12 m) tall wood utility pole with a bearing capacity of 2,400 lbs. (1,100 kg) typically weighs 1,100 lbs. (500 kg), whereas a composite pole of the same size and capacity made by his firm weighs just 305 lbs. (138 kg).
Composite poles are also more likely to bend than to break in very strong winds, making them preferable to poles of wood or concrete in tornado- and hurricane-prone regions or under ice loads, according to the manufacturers "Wood breaks at eighty-plus miles an hour," whereas Duratel's poles can withstand wind up to 150 mph (240 km/h), Williams says.
Some of the poles are sold in sections, making them easier to transport on smaller vehicles than would be the case with full-sized poles. Smith says his utility has opted for RS Technologies Inc.'s tapered pole sections, which can be nested inside one another, for use in residential backyards. "It's hard to get poles into a backyard," he says, and the labor costs of doing so are high.
Because their initial costs can be 2 to 20 times as much as those of poles made from more traditional materials, composite poles are unlikely to replace all other types anytime soon. But Smith says, "If you look at the way we use them, a high woodpecker area, or a high moisture area, you might only get a year to ten years out of a wooden pole." By contrast, the manufacturers say composite poles ought to last 40 to 125 years, even under harsh conditions.


5/06/2013 · Hi, I have just flashed to the latest CM10.1 and keep getting an annoying mobile broadcast notification. I found the option in settings and unticked all of the boxes, and it still pops up.... How to stop cell broadcast (ETWS) messages and notifications in android mobiles Hi guys..recently I have faced a problem in my friend mobile lenova a7000. In which the network provider gives lot of ETWS cell broadcast messages.
The app displays the cell broadcast message (if any)sent by the mobile operator on channel 50. It works in totally offline mode, doesn't require internet to update the cell broadcast.
A cell broadcast is a text message sent to the mobile phones of multiple recipients. This can be done using another mobile phone, but this is usually limited to 10 people at a time.
20/06/2013 · These notifications can be switched off. It can be done by going into the 'settings' and selecting 'wireless and networks' from it. From that option select 'more' and opt for 'cell broadcasts from it' and uncheck the option for receiving broadcasts.


text:
Home » German flour mills fined for anti-competitive behavior
German flour mills fined for anti-competitive behavior
BONN, GERMANY — The Bundeskartellamt said on Feb. 19 it has concluded its cartel proceedings against companies in the milling industry and imposed fines of €41 million euros on 22 companies, the association of German mills (Verband Deutscher Mühlen e.V.) and their representatives on account of their involvement in illegal agreements in the sale of flour.
A first fine of €24 million euros had already been imposed in the same proceeding in October 2011.
In February 2008, the Bundeskartellamt searched several milling companies in Germany after receiving information from the market about agreements on prices and quantities. Subsequently, several companies filed applications for leniency and offered their cooperation in clarifying the facts of the case.
"Since 2001 representatives of the milling companies involved had agreed on prices, customer allocation and supply volumes in regular rounds of talks. The agreements applied to all forms of flour distribution, i.e. to industrial customers (such as e.g. bakery product manufacturers and bakery chains), artisan bakers and the direct sale of flour in small packages (max. 1 kg packets) to food retailers," said Andreas Mundt, president of the Bundeskartellamt. "With the proceedings initiated in 2008, we have uncovered and put an end to this system of price, customer allocation and market sharing agreements in the milling industry which has been practiced over many years."
In addition, the companies coordinated capacity planning by shutting down mills or preventing mills which had already been shut down from being returned to operation.
In addition to VK Mühlen AG, which was already fined in October 2011, the following companies were involved in the agreements: Werhahn Mühlen GmbH & Co. KG, Georg Plange GmbH & Co. KG, Mühle Rüningen GmbH & Co. KG and Pfälzische Mühlenwerke GmbH, Grain Millers GmbH & Co. KG (with its subsidiaries Bremer Rolandmühle Erling GmbH & Co. KG, Mills United Hovestadt & Münstermann GmbH and Heyl GmbH & Co. KG), Saalemühle Alsleben GmbH, Flechtorfer Mühle Walter Thönebe GmbH, Gebr. Engelke Große Mühle Hasede-Hildesheim GmbH & Co. KG, Magdeburger Mühlenwerke GmbH, Oderland Mühlenwerke Müllrose GmbH & Co. KG, Hedwigsburger Okermühle GmbH, Thüringer Mühlenwerke GmbH, Albert Mühlschlegel GmbH & Co. KG, Friedrich Wilhelm Borgstedt Milser Mühle GmbH, Südhannoversche Mühlenwerke Engelke GmbH, Frießinger Mühle GmbH, Bliesmühle GmbH, Karl Bindewald Kupfermühle GmbH, Cramer Mühle KG, Heinrich Thylmann GmbH & Co. KG Kilianstädtermühle, Rheintal Mühlen GmbH and Heiss Mühle GmbH.
A representative of the association of German mills also participated in the cartel discussions and assisted the representatives from the various mills in organizing meetings of the cartel and coordinating the agreements.
The fines imposed on the individual companies are calculated according to the seriousness and duration of the involvement in the cartel. In addition, the economic viability of the companies involved was given special consideration in this particular case, also in view of the fact that the French and Dutch competition authorities have already imposed heavy fines on German mills for their involvement in other agreements. The proceedings were conducted in close cooperation with the competition authorities of the two neighboring countries.
In setting the fines, the Bundeskartellamt also took into account that in addition to VK Mühlen AG, the milling companies of the Werhahn group and Grain Millers group also cooperated extensively with the Bundeskartellamt in clarifying the accusations.
ConAgra facing fine for violations at Ohio flour mill
MF Global Holdings fined for role in brokerage collapse
Operations Manager required for a large Flour Milling Company in DRC


text:
Masood Entrepreneurship Centre
https://www.entrepreneurship.manchester.ac.uk
Manchester scientist lands prestigious British Council UK Alumni award
The founder of medtech start up ErleaDx has won the Business and Innovation category at the 2021 – 2022 British Council Study UK awards.
Dr. Na Yu (Cherry) Chia, who is working with the world's best doctors to develop a ground breaking early detection test for lung cancer, beat off stiff competition to land the accolade.
She was presented with her award at a ceremony in Singapore earlier this month.
Dr. Chia has been supported by the Masood Entrepreneurship Centre on her enterprise journey after her studies at the University of Manchester. Her pioneering work on a blood-based test to pick up lung cancer in its early stages is now attracting attention from the global scientific community.
She is currently working on product development and clinical recruitment for the Mirlung Dx lung cancer detector and hopes to have a prototype available to UK lung cancer patients by 2023.
ErleaDx's goal is to develop a handheld device for lung cancer detection which works in a similar way to glucose testing meters for diabetics.
Dr. Chia was one of the winners of the 2021 Venture Further Business Start-up Competition in the healthcare category for this early lung cancer detection project. Venture Further is the flagship annual start-up competition for all current students and recent graduates across the University of Manchester.


text:
As enchentes no Sudeste do Brasil em 2013 ocorreram após fortes chuvas atingirem partes dos estados brasileiros supracitados em dezembro daquele ano. Ao lado das enchentes de 1979, está entre os maiores desastres naturais já registrados na região, deixando 46 vítimas fatais e mais de 54 mil desalojados ou desabrigados, afetando um total de 155 municípios entre o território capixaba e a faixa leste do estado mineiro.

Chuvas

Antecedentes
As chuvas intensas em dezembro foram antecedidas por um inverno tipicamente seco e um outubro com chuvas moderadas e dentro da média na maior parte das áreas afetadas pelos temporais em dezembro, ao contrário de novembro, que foi marcado por veranicos e chuvas irregulares em algumas áreas do Espírito Santo e principalmente no leste mineiro. Em todos os pontos de monitoramento do Instituto Nacional de Meteorologia (INMET) situados na região mineira do Vale do Rio Doce as chuvas ficaram abaixo da média climatológica em novembro, exceto em Timóteo, onde o acumulado mensal foi de , para uma média de  (Governador Valadares, a cerca de 100 km de Timóteo, terminou o mês com menos de ). No entanto, em território capixaba choveu significativamente na maior parte do estado em novembro, sendo que as chuvas se concentraram no começo e no final do mês; Vitória fechou o mês com , sendo  apenas entre os dias 26 e 27.

Primeiras chuvas intensas
O primeiro decênio de dezembro foi marcado por altas temperaturas e tempo seco e, após o dia 5, ocorreram algumas chuvas expressivas, mas ainda mal distribuídas, provocadas pelo abafamento e por uma frente fria situada sobre o Oceano Atlântico, que dissipou-se no dia 9. Entre a tarde e a noite do dia 11 de dezembro, um forte temporal atingiu a Região Metropolitana de Belo Horizonte (RMBH), provocando vários pontos de inundação, enxurradas, interrupção no abastecimento de energia elétrica e desabamentos. Essas chuvas foram causadas pelo avanço de uma nova frente fria, agora sobre a região e, segundo o INMET, o acumulado de chuva na estação meteorológica automática da Pampulha, em Belo Horizonte, entre as 10 horas da manhã do dia 11 e as 10 horas do dia 12 foi de .

Durante a madrugada do dia 12, a frente fria avançou sobre o leste mineiro e Espírito Santo, provocando chuvas fortes e estragos em algumas cidades do estado capixaba e do Vale do Rio Doce, como na Região Metropolitana do Vale do Aço, onde o acumulado na estação meteorológica de Timóteo foi de . Em Aimorés choveram  entre os dias 11 e 13 e em Governador Valadares choveram  no dia 13. No Espírito Santo, choveram  em Vitória no dia 12 (mais da metade da média climatológica do mês de dezembro) e em Linhares ocorreram  no dia 13. O Rio Doce começava a apresentar uma elevação em seu nível, provocando enchentes em algumas cidades.

ZCAS

A frente-fria, associada à umidade oriunda da Amazônia, começava a dar origem à formação da zona de convergência do Atlântico Sul (ZCAS). Previam-se acumulados significativos para Minas Gerais e Espírito Santo. O Instituto Capixaba de Pesquisa, Assistência Técnica e Extensão Rural (Incaper) emitiu, no dia 16 de dezembro, um alerta de chuvas moderadas e fortes, com possíveis rajadas de vento e raios, para o dia seguinte no Norte, Noroeste e Nordeste do Espírito Santo, mantendo as regiões em estado de atenção. Voltou a chover com bastante intensidade no Espírito Santo ainda na noite do dia 16.

Segundo o Incaper, do dia 1º ao dia 19 de tal mês, choveram  em Pontal do Ipiranga,  em Povoação (ambos no município de Linhares),  em Águia Branca,  em Sooretama,  em Vitória e  em Viana. Entre os dias 17 e 19, Linhares foi a região litorânea com maior precipitação no mundo, segundo imagens do satélite Tropical Rainfall Measuring Mission (TRMM) da NASA. Em Minas, choveu cerca de  em Governador Valadares entre os dias 16 e 17, o que significa 67% acima da média climatológica do mês inteiro. Segundo o INMET, entre os dias 16 e 19 choveram  em Aimorés e  em Capelinha.

Choveu continuamente entre o leste mineiro e o Espírito Santo até por volta do dia 25 de dezembro (Natal), quando o sistema começou a enfraquecer, e após o dia 26 as chuvas vieram em forma de pancadas isoladas, porém fortes em alguns pontos, associadas ao calor e à alta umidade. Em Minas Gerais, foram registrados  em Timóteo entre os dias 20 e 22 ( do dia 1º a 31 de dezembro),  entre os dias 20 e 23 em Governador Valadares ( entre os dia 1º e 31),  em Capelinha entre os dias 20 e 23 ( entre os dia 1º e 31), e  em Aimorés entre os dias 20 e 24 ( entre os dias 1º e 31). No Espírito Santo, o acumulado mensal mensal de dezembro foi de  em Linhares,  em Vitória (sendo  entre os dias 19 e 24) e  em Santa Teresa (com acumulado diário de  em 21 de dezembro e  no dia 24).

Danos

Primeiras chuvas
No dia 5 de dezembro, Caratinga registrou a segunda morte do período chuvoso no estado de Minas Gerais em decorrência de temporais, onde uma adolescente de 12 anos morreu soterrada em um deslizamento de terra; a primeira vítima foi em Astolfo Dutra, na Zona da Mata, no dia 4 de outubro, quando um agricultor foi atingido por um raio. No dia 12, com o avanço da frente-fria que viria a dar origem à ZCAS, houve deslizamento de terra, quedas de árvores e alagamentos nos municípios da Região Metropolitana de Belo Horizonte e no Vale do Aço (Ipatinga, Coronel Fabriciano e Timóteo), em Minas Gerais. No Espírito Santo, em Bom Jesus do Norte o temporal daquele dia deixou 100 pessoas desalojadas e em Vitória ruas e avenidas ficaram alagadas. As chuvas contínuas provocaram um aumento no nível do rio Doce e, posteriormente, as primeiras enchentes a partir do dia 14 de dezembro em cidades como Governador Valadares e Linhares.

Espírito Santo

No Espírito Santo, em 16 de dezembro, os rios Bananal, Timirim, Panorama e Bananalzinho não suportaram o volume de chuva e alagaram o município de Rio Bananal. Até então, este era o município mais prejudicado, sofrendo a maior enchente de sua história, com o rio Bananal cinco metros acima do nível normal. A enxurrada invadiu todo o comércio da cidade, fazendas e centenas de casas, destruiu pontes e ruas, interrompeu o fornecimento de água potável e energia elétrica e comprometeu a telefonia. Segundo a coordenadora da Defesa Civil de Rio Bananal, a cidade ficou praticamente devastada. Duas casas foram arrastadas pelas águas e a cidade ficou com todas as estradas bloqueadas. Três mil pessoas ficaram desalojadas e 350 desabrigadas.

Ainda em 16 de dezembro, as fortes chuvas provocaram a cheia dos córregos Laranja da Terra e São José, no município de Laranja da Terra. Em Marilândia, o rio Liberdade transbordou e inundou ruas. Em Bom Jesus do Norte, o rio Itabapoana ameaçou transbordar. Em Cachoeiro de Itapemirim, onde chovia desde o dia 13, dois muros e uma barreira caíram na avenida Jones dos Santos Neves, no bairro Caiçara. Em Castelo, houve deslizamentos, uma ponte entre os bairros São Pedro e Corumbá e um muro caíram, e quinze casas e duas escolas foram inundadas. Em Viana, houve alagamentos nos bairros Vila Bethânia, Santo Agostinho, Universal, Ipanema, Industrial e Campo Verde. Em Vila Velha, houve deslizamento no bairro 23 de Maio. Em Cariacica, o bairro Flor de Piranema foi inundado e em Nova Rosa da Penha I houve deslizamento. Em Laranja da Terra, houve alagamentos, e em Governador Lindenberg e Itarana, houve deslizamentos. Em Castelo, o rio Castelo subiu 2,7 metros e foram destruídos uma ponte e dois muros. Em Mimoso do Sul, houve cheia no rio Muqui, e em Vargem Alta, 90% das estradas foram danificadas.

Em Vila Velha, entre os dias 17 e 18 de dezembro, os bairros de Cobilândia e Paul ficaram alagados, e no bairro Ataíde houve queda de um muro, que resultou na destruição de dois caminhões e danificação de outro muro. Em Laranja da Terra, o rio Guandu subiu cinco metros. Uma casa desabou no Morro do Moscoso, em Vitória, e outra desabou no bairro Bandeirantes, em Cariacica. Na noite do dia 18, um deslizamento interditou a curva do Saldanha. Em Conceição do Castelo, o rio Castelo subiu quatro metros, causando inundações e quedas de barreiras.

No dia 19, o rio Fundão chegou a 3,70 m acima do nível normal, mas ainda não tinha transbordado no município de Fundão. Em João Neiva, o rio Clotário subiu cinco metros, atingindo principalmente o Centro e as localidades de Monte Líbano, Cavalinhos, Acioli e Vila Nova de Baixo. Na cidade, a água invadiu casas e comércios da parte baixa da avenida Getúlio Vargas, isolou pessoas e derrubou árvores sobre vias. Em Vila Pavão, houve quedas de barreiras, bloqueios de estradas e destruição de casas, bueiros e pontes. Pessoas ficaram isoladas e desabrigadas nas localidades de São Gonçalo e Beira-Rio. Em São Mateus, houve desalojados nos bairros Porto, Maruim e Pedra d'Água. À noite, em Vitória, um muro caiu em Jucutuquara, um deslizamento ocorreu no Jaburu e uma rocha caiu em Consolação. Em Vila Velha, ruas ficaram alagadas no bairro Cristóvão Colombo, Itapoã e Praia da Costa. A Terceira Ponte ficou fechada por quatro horas. Ficaram sem abastecimento de água pela Companhia Espírito-Santense de Saneamento (Cesan) os municípios de Água Doce do Norte, Águia Branca, Alto Rio Novo, Barra de São Francisco, Nova Venécia, Pancas, São Gabriel da Palha e Vila Valério.

Em 20 de dezembro, o rio Cricaré subiu três metros em Nova Venécia e deixou duas pontes submersas, uma passarela destruída e a localidade de São Gonçalo isolada. A estrada que liga Nova Venécia a São Mateus ficou interrompida pelo Departamento Nacional de Infraestrutura de Transportes (Dnit). Em Viana, 190 famílias ficaram desabrigadas e os bairros Marcílio de Noronha, Jucu, Nova Belém e Ipanema ficaram com risco de deslizamentos. Ruas da Prainha, em Vila Velha, foram tomadas por areia e o calçamento do Convento da Penha foi arrastado pela força da água. Nos bairros de Jardim Garanhuns, Ulisses Guimarães e Ataíde, houve alagamentos, deslizamentos e quedas de muros. O município de Santa Leopoldina ficou isolado com a subida do rio Santa Maria da Vitória, que obstruiu a rodovia que liga a cidade a Santa Maria de Jetibá e Cariacica. Em Marechal Floriano, o Braço Norte do Rio Jucu subiu dois metros e inundou casas e terrenos. Em Cariacica, o rio Formate subiu dois metros. Em Pancas, bairros foram alagados, e pontes e bueiros foram destruídos. Barra de São Francisco ficou completamente alagada. Em São Domingos do Norte, o rio São José encheu e deixou desabrigados. Em Guarapari, houve deslizamentos, havendo desalojados no bairro Kubitschek. Casas ficaram danificadas em Ibatiba.

No dia 22, na Serra, uma casa desabou em Cidade Pomar e houve deslizamento em Vista da Serra I. Mais de trinta linhas do transporte coletivo (Transcol) foram desviadas. Quase todas as rodovias estaduais foram afetadas. Na rodovia ES-010, entre Jacaraípe e Nova Almeida, na Serra, a pista foi parcialmente destruída. O nível do rio Doce continuava elevado e com tendência a subir, provocando enchentes em cidades como Baixo Guandu, Colatina e Linhares entre os dias 20 e 26. Cerca de 20 mil quilômetros de estradas foram danificados no estado.

Minas Gerais
Em 17 de dezembro, um deslizamento de terra deixou seis mortos na zona rural de Sardoá, em Minas Gerais. Foi aberta uma clareira de 100 metros em meio à plantação de eucalipto. As cidades de Ataléia, Capelinha, Vargem Alegre, Santos Dumont, Rio Pardo de Minas, Comercinho, Conselheiro Pena, Mantena, São João do Manteninha, Resplendor, Mathias Lobato e  São João Evangelista também foram afetadas por fortes chuvas entre os dias 15 e 19, com registros de inundações e alagamentos. Em Governador Valadares, a prefeitura considera o temporal que atingiu a cidade entre os dias 17 e 18 como "um dos piores da história da cidade", sendo que cerca de 250 pessoas ficaram desalojadas, houve desabamento de uma casa e o trânsito foi paralisado em diversos pontos. No dia 18, entre as regiões Central, Vale do Rio Doce, Noroeste, Zona da Mata e Vale do Jequitinhonha, oito estradas apresentavam trechos interditados. No dia 19, as viagens do trem de passageiros da Estrada de Ferro Vitória a Minas (EFVM) foram suspensas e o excesso de chuva prejudicou ainda a agricultura, como o cultivo do café.

Entre a noite do dia 20 e a madrugada do dia 21, as fortes chuvas provocaram deslizamentos de encostas, desabamentos e inundações em Coronel Fabriciano, Ipatinga e Timóteo, com registros de deslizamentos de terra nos bairros Ana Rita (Timóteo), Mangueiras (Coronel Fabriciano) e Bom Jardim (Ipatinga). A queda de uma barreira interditou a BR-381 por mais de dez horas e o desvio precisou ser feito por dentro do perímetro urbano de Timóteo e Coronel Fabriciano. Entre os dias 22 e 23, houve registros de novos deslizamentos em Ipatinga e Governador Valadares, que provocaram mortes e em 24 de dezembro, cinco bairros da cidade de Aimorés ficaram alagados e três casas desabaram, sendo que a cidade já havia sido afetada por outro temporal no dia 18. Entre a noite do dia 26 e a madrugada do dia 27 voltou a chover forte na região do Vale do Aço, sendo Coronel Fabriciano a cidade mais atingida, onde o ribeirão Caladão, que corta o perímetro urbano, transbordou e provocou enchentes em todo o seu curso, afetando os bairros situados às margens. Após o temporal, a prefeita da cidade, Rosângela Mendes, afirmou que viu tamanhos estragos na cidade somente na enchente de 1979.

No total, cerca de 2 mil pessoas ficaram desabrigadas em Aimorés. Nas três cidades do Vale do Aço, o total de desalojados até o dia 26 de dezembro era de  pessoas ( em Ipatinga, 110 em Timóteo e 40 em Coronel Fabriciano) e em Governador Valadares havia 669 pessoas desalojadas, sendo que nesta cidade vários bairros ficaram dias seguidos com os serviços energia elétrica e abastecimento de água prejudicados.

Reações

Postos de doações foram estabelecidos em batalhões da Polícia Militar em Vitória, Nova Venécia, Vila Velha, Barra de São Francisco e Linhares. A Cruz Vermelha recebe donativos na Praça do Papa e estabelecimentos públicos e privados também recebem doações em várias cidades capixabas. Igrejas católicas da diocese de Colatina, através da Cáritas Diocesana de Colatina, recolheram doações para as vítimas da enchente de Rio Bananal. Em Cariacica, escoteiros, membros da Igreja Catolica e da Ordem DeMolay receberam doações. Esportistas e a Secretaria de Estado de Esportes e Lazer realizaram a campanha #esportesolidario para arrecadar donativos.

Para o atendimento de emergências, o Corpo de Bombeiros Militar do Estado do Espírito Santo e a Defesa Civil ficaram de plantão. Todo o efetivo dos Bombeiros foi acionado para atender à crise. O Departamento de Estradas de Rodagem do Espírito Santo (DER-ES) ficou de plantão para agir nos casos que comprometessem o trânsito em rodovias estaduais. O Banco de Desenvolvimento do Espírito Santo (Bandes) ofereceu o crédito Bandes Emergencial para atender pequenas empresas e empreendedores, formais ou informais, que comprovarem perdas materiais com as chuvas.

No dia 19 de dezembro, entidades do governo do Espírito Santo se reuniram para definir metas de ação. O governador Renato Casagrande contactou os ministros da Casa Civil, Gleisi Hoffmann, e da Integração Nacional, Francisco Teixeira, para pedir ajuda do governo federal. No dia seguinte, Casagrande, Teixeira, o subchefe da Casa Civil Luís Antônio Padilha, o secretário nacional da Defesa Civil Adriano Pereira Júnior, o vice-governador Givaldo Vieira e o o chefe estadual da Defesa Civil Marcelo D'Isep sobrevoaram a Grande Vitória e visitaram Rio Bananal. No dia 21, Casagrande decretou estado de emergência em todo o Espírito Santo.

O prefeito de Vila Velha, Rodney Miranda (DEM), viajou com a família para passar dez dias de férias em Nova York, sendo a autoridade a única que poderia decretar eventual situação de emergência no município. Dada a repercussão negativa do caso, o prefeito antecipou sua volta ao Brasil.

Vítimas
Segundo a Defesa Civil, até o dia 31 de dezembro, no Espírito Santo havia sido contabilizado um total de 24 mortos, além de  desabrigados ou desalojados nessa mesma data (excetuam-se os que já haviam retornado às suas casas). Foi decretado estado de emergência em todo o estado no dia 21 de dezembro. No último dia de 2013, Minas Gerais contabilizava 22 mortes, 150 feridos,  desalojados e  desabrigados, além de  casas danificadas e 253 destruídas. Um total de 73 municípios decretaram estado de emergência e dois (Sardoá e Virgolândia) calamidade pública no estado mineiro.

Sudeste 2013
Desastres no Espírito Santo
Desastres em Minas Gerais
Sudeste Brasil
2013 no Brasil


text:
Pharmacy & Pills
Tag Archives: Holocaust
Trump appoints speechwriter fired for attending conference with white nationalists to commission that preserves Holocaust memorials
November 19, 2020 Sexual Health
Yahoo News – Latest News & Headlines
German Auschwitz prosecutor recalls powerful tales from Holocaust survivors
January 27, 2020 Sexual Health
Of the hundreds of testimonies he heard from survivors of the Nazi death camp at Auschwitz, retired German prosecutor Gerhard Wiese says the one that touched him most was of a Jewish father who had tried but failed to save his twins from the gas chamber. The father had offered his children to Josef Mengele, the Nazi officer known as the Angel of Death for his inhumane genetic experiments focused on twins, hoping they stood a better chance of survival. "After this witness statement there was absolute silence in the room," said 91-year-old Wiese, as Germany and the world mark the 75th anniversary of the liberation of Auschwitz.
Dutch Prime Minister apologizes for country's role in Holocaust
Dutch Prime Minister Mark Rutte said on Sunday he was sorry for his country's role during the Holocaust and the lack of action against the persecution of Jews, becoming the first Dutch premier to make such an official apology. "With the last remaining survivors among us, I apologize on behalf of the government for the actions of the government at the time", Rutte said at an event in Amsterdam to mark the 75th anniversary on Monday of the liberation of the Auschwitz death camp. Earlier Dutch governments have made apologies for the way Jews who survived World War Two atrocities were treated when they returned home from concentration camps, but have shied away from condemning the country's part in the persecution of Jews and other minorities during the German occupation.
For Marija Frlan it's as symbolic as it can get: A survivor of a Nazi concentration camp during World War II, the Slovenian woman turns 100 years old on Monday, the international Holocaust Remembrance Day. Frlan, who was held at the Nazi's Ravensbruck camp in northern Germany for over a year in 1944-45, will join other survivors and officials in Poland on Monday for ceremonies marking the 75th anniversary of the liberation of the Auschwitz death camp. "The ones who didn't survive this, they can't understand, no," the energetic woman said at her home in the small village of Rakek in southwestern Slovenia.
Jewish groups condemn Trump lawyer Rudy Giuliani after he said Holocaust survivor George Soros is 'hardly a Jew'
December 26, 2019 Sexual Health
Jewish groups have hit out at Donald Trump's personal lawyer Rudy Giuliani after the former New York mayor claimed he was "more of a Jew" than financier and Holocaust survivor George Soros.Mr Giuliani, who is of Italian descent and was raised Catholic, told New York Magazine Mr Soros had employed FBI agents and instated ambassadors – playing into conspiracy theories about the level of the philanthropist's control.
Rudy Giuliani: 'I'm more of a Jew' than George Soros, a Holocaust survivor
Trump's personal lawyer Rudy Giuliani claimed that he is "more of a Jew" than George Soros, a Holocaust survivor, in an interview published Monday.
A major Jewish group slammed Rudy Giuliani for saying George Soros, who survived the Holocaust, is 'hardly a Jew'
The Anti-Defamation League said comments from Giuliani — Donald Trump's lawyer — about George Soros could serve as a dog-whistle to anti-Semites.
Holocaust architect's grave dug up in Berlin
The grave of a top Nazi who helped plan the Holocaust and was assassinated by British-trained agents during World War II has been dug up in Berlin, German police said on Monday. The grave of Reinhard Heydrich was "dug up in the night between Wednesday and Thursday" and an investigation has been opened on charges of disturbing a burial site, a police spokeswoman told AFP. Heydrich was the powerful head of Hitler's Reich Security Office, which included the Gestapo.
Activists apologize for use of Holocaust victims' remains
December 5, 2019 Sexual Health
An activist group has apologized to Jewish organizations outraged over their use of purported Holocaust victims' remains in an installation outside Germany's parliament building meant to draw attention to the perils of far-right extremism. The Center for Political Beauty, a Germany-based activist group known for provocative stunts, installed an urn outside the Reichtstag building on Monday, saying it contained victims' remains that it had unearthed from 23 locations near Nazi death and concentration camps in Germany, Poland and Ukraine. Following the uproar from Jewish organizations decrying the stunt as an instrumentalization of the Holocaust and an affront to the dead, the group apologized and by Thursday morning the urn had been wrapped in opaque black plastic so its contents could not be seen.
Poland Rebukes Netflix After 'Terrible Mistake' on Holocaust
(Bloomberg) — Poland's prime minister wrote an official letter to Netflix Chief Executive Officer Reed Hastings requesting that the media streaming company correct facts about the Holocaust in its "The Devil Next Door" documentary series.The European Union member lurched into the international spotlight last year after its nationalist ruling Law & Justice party outlawed the phrase "Polish death camps." It also criminalized suggesting that the nation was complicit in the mass murder of Jews and other people by the Nazis during their occupation of the country in World War II.A Netflix spokesperson said the company is "aware of the concerns" about the show and is "urgently looking into the matter" after Prime Minister Mateusz Morawiecki wrote to Hastings.Morawiecki called out Netflix for what he called "a terrible mistake" in the five-part series. The show focuses on John Demjanjuk, a retired Ford Motor Co. auto mechanic who was stripped of his U.S. citizenship and convicted by a German criminal court for aiding in the murder of Jews during the Holocaust.The series showed a map of death camps that said they were located in Poland, using the country's current borders.The Polish government has repeatedly pushed for commentary on the death camps to label them as being operated by the Nazis in "German-occupied Poland," because the eastern European nation had no government of its own on its home soil after the invasion of Adolf Hitler's forces."Not only is the map incorrect, but it deceives viewers into believing that Poland was responsible for establishing and maintaining these camps," Morawiecki wrote, saying he believed it was an "unintentional" mistake. "Today, we still owe this truth to the victims of World War II."Morawiecki enclosed a 1942 map in the letter, which was backed by a comment from the Auschwitz Memorial saying that "more accuracy" should have been expected from the production.(Updates with details of complaint in sixth paragraph.)To contact the reporter on this story: Maciej Martewicz in Warsaw at mmartewicz@bloomberg.netTo contact the editors responsible for this story: Wojciech Moskwa at wmoskwa@bloomberg.net, Michael WinfreyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Health Life - Video
about After against Attack Biden border California calls China Could court dead deal Death Democrats Donald election Fire first Florida Found from House Into Iran killed Korea latest more North over People police President Report Russia Says shooting state Syria This Trump U.S. White woman
Biden will be inaugurated amid high security, before a 'Field of Flags' instead of people
The WHO warns of "catastrophic moral failure" over coronavirus vaccine access
Auto Repair Charlotte
© 2021 Health Life